Key Highlights
- On Thursday, November 19, 2026, SELLAS Life Sciences (NASDAQ:SLS) slid 13.98% in trading, a move that followed the launch of a USD 150.0 million proposed underwritten offering. Underwriters could take up to USD 22.5 million more within 30 days.
- ClearOne (NASDAQ:CLRO) fell 11.59% after finishing a USD 4.00 per share issuance of 999,999 shares on November 17, 2026, which raised its shares outstanding to 3,675,411.
- PepGen (NASDAQ:PEPG) rose 8.82% despite a USD 5.00 per share offering of 25 million shares dated November 11, 2026, a transaction projected to generate USD 125 million before fees.
- newcleo (NASDAQ:NWCL) lost 6.9% after filing, on November 18, 2026, a prospectus supplement that could cover as many as 217,834,936 ordinary shares, a figure that works out to 77% of shares outstanding (calculated).
SELLAS Life Sciences (NASDAQ:SLS): USD 150 Million Offering Follows a Trial Win
Trading on Thursday, November 19, 2026 saw SELLAS Life Sciences (NASDAQ:SLS) fall 13.98% at midday, which points to a prior close around USD 17.95 (calculated). Galinpepimut-S, tested in acute myeloid leukemia within the REGAL Phase 3 study, had produced a positive overall survival outcome two days earlier, on November 17, 2026: median survival reached 24.0 months, compared with 14.7 months under best available therapy. That same day the company unveiled a proposed public offering totaling USD 150.0 million, with J.P. Morgan and TD Cowen acting as joint book-running managers, and underwriters may exercise an extra USD 22.5 million option inside a 30-day window. All of the shares come from the company itself, which spreads ownership across a bigger pool. Pricing per share and intended use of funds were not disclosed, and final terms remain unconfirmed. At the end of September 2026 cash stood at USD 134.7 million, and the third quarter closed with a USD 10.1 million net loss. Management plans to meet the FDA about an accelerated filing path and to get a Biologics License Application ready for the first half of 2027. Weak points include an open-label study enrolling 126 patients, a p-value of 0.035 that only just clears the 0.05 threshold, and an offering whose conditions are not guaranteed. With no other company announcement located, dilution looks like the leading explanation, though nothing confirms it.
ClearOne (NASDAQ:CLRO): USD 4.00 Share Issue Under Nasdaq Scrutiny
ClearOne (NASDAQ:CLRO) slid 11.59% on November 19, 2026, despite a prior close around USD 6.90 (calculated), a price far above the USD 4.00 at which new shares were placed. Issuance of 999,999 shares at USD 4.00 concluded on November 17, 2026, generating total consideration of USD 3,999,998. Gross cash before costs was close to USD 2.756 million, and First Finance, the biggest shareholder, converted USD 1,244,458 owed to it, interest included, into 311,114 shares. That leaves 3,675,411 shares outstanding, with the fresh stock making up roughly 27% of that total (calculated). Behind the transaction sits a dispute with the exchange: Nasdaq staff ruled on October 8, 2026 that the company was below the USD 2.5 million minimum Equity threshold, and a hearing had been scheduled for November 17, 2026. A pro forma equity figure of USD 3.282 million, described as preliminary and unaudited, has been submitted, and audit changes and future losses may reduce it, and Nasdaq has yet to acknowledge that the shortfall is resolved. Some published reporting also cited zero ongoing Revenue and a planned combination with Cortigent and Vivani Medical, but neither point has been verified here. No standalone company statement came with the decline, and since the float is thin, a handful of trades can move the quote.
PepGen (NASDAQ:PEPG): Gaining While Still Under Its Offering Price
PepGen (NASDAQ:PEPG) climbed 8.82% to USD 4.16 on November 19, 2026, but the quote still sits about 16.8% under the USD 5.00 deal price, a figure from simple arithmetic on two published values. Among the four names, it was the only one to finish higher. Its sale of 25 million shares was priced at USD 5.00 a share on November 11, 2026, a transaction expected to Yield USD 125 million before fees, with a 30-day underwriter option on as many as 3.75 million extra shares. That followed Phase 2 findings for PGN-EDODM1 in myotonic dystrophy type 1, in which the 10 mg/kg dose achieved an average splicing correction of 46.5%. Cash at September 30, 2026 was USD 104.8 million, and including the gross proceeds the figure reaches approximately USD 229.8 million before costs and subsequent spending (calculated). On a net basis, the third quarter produced a USD 19.4 million loss. A partial clinical hold imposed by the FDA in March 2026 is the principal threat, and a regulatory meeting now being planned depends on that hold being lifted. No company news dated November 17 to 19 was found, so the advance cannot be attributed to a new development, and completion of the offering has not been verified.
newcleo (NASDAQ:NWCL): Resale Filing Sits Beside Growing Cash Reserves
newcleo (NASDAQ:NWCL) dropped 6.9% on November 19, 2026. The implied prior close of USD 3.77 (calculated) already sat beneath the USD 4.01 close recorded on November 17. The day before that move, on November 18, 2026, the company put out its third-quarter update and lodged a prospectus supplement that could cover as many as 217,834,936 ordinary shares, together with 9,146,717 shares tied to warrants. Shares outstanding stood at 281.5 million at September 30, 2026. No offering price appears in the filing, and the excerpt examined did not state the reason for it, although documents of this kind usually let holders resell registered stock. The company did not announce any new Capital raise. Cash rose to 233.4 million euros from 90.4 million euros a year before, and product and service revenue grew by roughly 26%, reaching 9.95 million euros. A developer of lead-cooled reactors entered Nasdaq trading on September 22, 2026 by way of a Merger with a blank-check vehicle. Threats include a sizable block of registered shares possibly reaching the market, minimal revenue relative to capital outlays, delays at its Italian demonstrator project and licensing obstacles. Searches located no company announcement describing the decline, and low-priced stocks can display wide bid-ask spreads.
Where Things Stand
Reactions were mixed. SELLAS Life Sciences (NASDAQ:SLS) gave up 13.98% in the session, the largest drop of the group, while ClearOne (NASDAQ:CLRO) lost 11.59% after its USD 4.00 share sale, which enlarged the share count by about 27%. newcleo (NASDAQ:NWCL) retreated 6.9% amid a resale filing that adds no fresh cash. PepGen (NASDAQ:PEPG) moved up 8.82%, yet it trades below the USD 5.00 offering price. Just two of the four tie a clearly disclosed, company-declared share sale to the trading day, and no company has verified what drove any move. Upcoming checkpoints are the final pricing for SELLAS, the Nasdaq panel decision for ClearOne, the closing of the PepGen transaction and any selling by holders under the newcleo filing. None of this assures future price action.






Please wait processing your request...